- It seems that 2007 should be a brighter year for Johnson & Johnson (NYSE JNJ). In 2006 the company faced major drug expirations which dampened revenue growth.
- I really like the Pfizer’s (PFE) consumer business acquisition. Despite having a fairly good product line, Pfizer Inc was a pharmaceutical company that happened to have consumer products which came with the Warner Lambert acquisition. JNJ on the other hand has a culture of running diverse healthcare and consumer businesses.
- It reminds me of 3M Company (NYSE MMM), as there is a synergy between different operating units as they share their R&D findings.
- JNJ has a greater global consumer distribution network than Pfizer, therefore, it will be able to increase sales of PFE’s consumer unit by taking the products to places that they’ve not gone before (sounds Star Treckish, doesn’t it?)
- Abbott Laboratories (ABT) received an incredible price (34 times operating earnings) for its diagnostic unit that was sold to General Electric (NYSE GE) (great job!).
- I always looked at ABT as a mini-JNJ; it is a diversified healthcare company which is not heavily dependent on blockbusters. The company had a good quarter and should have a good next year. It is trading at about 18x earnings, higher valuation than JNJ’s 15x earnings, but it should have a bit higher growth rate.
Please read the following important disclosure here.
Enjoyed this read?
Share it with someone who’d love it too!
New to investing?
Explore these valuable guides to get started.
Related Articles
Living and Investing with Intention
As an investor, being intentional about identifying assumptions is extremely important. When you're mindless, you accept things as they are without realizing you're walking on thin ice while everyone else thinks it's solid ground.
Quality Matters: From Paris to Portfolios
Today I am a different (hopefully better) investor than I was five, ten, twenty years ago; as I look at the biggest changes, it is my focus on quality investing and being extremely selective and uncompromising when it comes to quality.
Q&A Series: Research Process, Evaluating Country Risk and Tech Investments
Today we'll delve into my research process, how I assess country risk for investments and why some investors avoid technology stocks
Omaha 2026 Breakfast + Get Together
If you’re making the pilgrimage to Omaha for the Berkshire Hathaway Annual Meeting, I’d love to see you there. Every year, thousands of value investors gather to celebrate the wisdom of Buffett and Munger, but my favorite part has always been connecting with readers and friends over coffee.
0 comments
0